Analyst Price Target is $55.00
▲ +511.11% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Impel Pharmaceuticals in the last 3 months. The average price target is $55.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 511.11% upside from the last price of $9.00.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Impel Pharmaceuticals.
Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Read More